105 results
424B3
RGBP
Regen BioPharma Inc
24 Apr 24
Prospectus supplement
1:28pm
of the Company’s products, capital expenditures, financing needs, as well assumptions related to the forgoing. For this purpose, any statements contained
424B3
RGBP
Regen BioPharma Inc
19 Jan 24
Prospectus supplement
1:29pm
. For this purpose, any statements contained in this Quarterly Report that are not statement of historical fact may be deemed to be forward-looking
424B3
RGBP
Regen BioPharma Inc
20 Nov 23
Prospectus supplement
9:38am
Corporation, an FDA Specialist Group and Global Regulatory and Scientific Experts, for the purpose of review and guidance with regard to the planned … Regulatory and Scientific Experts, for the purpose of review and guidance with regard to the planned reinstatement of the Company’s inactive Investigational
424B3
f0s3yerbz3xub4n1j
2 Oct 23
Prospectus supplement
1:42pm
8-K
EX-10.1
9ue6pt
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.4
mrr8rs6eny
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.2
uju ujfwpb8
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.3
f6zv9vvc7jwne
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
424B3
h33 7xbos0kntxj
15 May 23
Prospectus supplement
10:25am